-
Lilly launches Phase I trial of investigational COVID-19 antibody treatment
europeanpharmaceuticalreview
June 05, 2020
The enterprise announced the initiation of the LY-CoV555 COVID-19 antibody treatment trial at medical centres across the US.
-
Memo Therapeutics discovers neutralising antibodies against Covid-19
pharmaceutical-technology
June 05, 2020
Switzerland-based Memo Therapeutics has discovered multiple SARS-CoV-2 neutralising antibodies with the potential for development as immunotherapy against Covid-19.
-
Lilly, AbCellera Dose First Patients with COVID-19 Antibody
contractpharma
June 02, 2020
Phase 1 study of LY-CoV555 is the world's first study of a potential antibody treatment designed to fight COVID-19.
-
AbCellera raises $105m for antibody drug discovery platform
pharmaceutical-technology
May 28, 2020
Canadian biotech firm AbCellera Biologics has raised $105m in a Series B funding round to advance its artificial intelligence (AI)-powered antibody drug discovery platform.
-
Potential Anti-SARS-CoV-2 Antibody Able to Inhibit In Vitro Virus Infection in Preclinical Studies
americanpharmaceuticalreview
May 19, 2020
Sorrento Therapeutics announced anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration.
-
Sorrento’s antibody completely blocks Covid-19 in-vitro
pharmaceutical-technology
May 19, 2020
Sorrento Therapeutics has reported that its Covid-19 therapeutic antibody candidate, STI-1499, can completely block the viral infection in-vitro during preclinical studies.
-
Vyriad to Develop Antibody Test to Determine COVID-19 Protective Immunity
americanpharmaceuticalreview
May 18, 2020
Vyriad has completed the development of a serology test to measure protective immunity against SARS-CoV-2, the novel coronavirus that causes COVID-19.
-
FairJourney Biologics Joins Forces with Iontas
contractpharma
May 14, 2020
FairJourney Biologics and Iontas, two Clinical Research Organizations (CROs) in antibody discovery services, have combined their operations to create an international platform and provide their industry leading services to global biopharma.
-
Junshi, Lilly to Co-develop Antibody Therapies for COVID-19
contractpharma
May 13, 2020
Multiple neutralizing antibodies have been engineered, with the lead asset poised to enter clinical testing in the second quarter.
-
Sorrento, Mount Sinai to Develop COVI-Shield Antibody Therapy
contractpharma
May 13, 2020
Sorrento Therapeutics Inc. and Mount Sinai Health System have agreed to join forces in the investigation and development of an antibody cocktail (COVI-Shield) to potentially treat COVID-19.